Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Yoshikazu, Tasaki"'
Autor:
Koichi Yoshida, Motofumi Kawai, Tsugiaki Utsunomiya, Akihiro Ishibazawa, Young-Seok Song, Mariana Sayuri B. Udo, Yoshikazu Tasaki, Akitoshi Yoshida
Publikováno v:
International Journal of Ophthalmology, Vol 15, Iss 3, Pp 388-393 (2022)
AIM: To investigate changes in extracellular matrix (ECM) gene expression in human trabecular meshwork (HTM) cells in response to mechanical fluid flow stimulation. METHODS: HTM cells were grown on a glass plate coated with 0.02% type I collagen (COL
Externí odkaz:
https://doaj.org/article/529a7b8ba29a4ad0ae2d4d6a171c9251
Autor:
Masumi OGAWA, Takayuki MANABE, Yuko KONDO, Sachie HATAYAMA, Kanae TANI, Miyuki SATO, Mariko YOKOYAMA, Kazumi YUKI, Naoya KAMIYAMA, Masaru HONMA, Yoshikazu TASAKI, Seiji MATSUMOTO
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 54:71-75
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56b9e5a95cf9c91f0bd255bb6d141626
https://doi.org/10.3999/jscpt.54.2_71
https://doi.org/10.3999/jscpt.54.2_71
Autor:
Shin Kashima, Hiroki Tanabe, Mishie Tanino, Yu Kobayashi, Yuki Murakami, Takuya Iwama, Takahiro Sasaki, Takehito Kunogi, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Kentaro Moriichi, Masahide Fukudo, Yoshikazu Tasaki, Masao Hosokawa, Yusuke Mizukami, Mikihiro Fujiya, Toshikatsu Okumura
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: Immuno-oncology is a novel target of cancer therapy. Nivolumab is a monoclonal anti-programed death-1 antibody recently used to treat patients with chemotherapy-resistant gastric and gastroesophageal cancer. Although the disease control r
Externí odkaz:
https://doaj.org/article/ac0780f2484944a4b105ac53d27066cb
Autor:
Masayuki Chuma, Hirofumi Hamano, Takashi Bando, Masateru Kondo, Naoto Okada, Yuki Izumi, Shunsuke Ishida, Toshihiko Yoshioka, Mizuho Asada, Takahiro Niimura, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Koji Miyata, Kenta Yagi, Sachiko Kasamo, Yuki Izawa‐Ishizawa, Momoyo Azuma, Hiroaki Yanagawa, Yoshikazu Tasaki, Keisuke Ishizawa
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. 131:525-535
There has been growing concern in worsening survival and renal outcomes following vancomycin-associated nephrotoxicity (VAN) onset, but the factors associated with these phenomena remain unclear. To examine these factors, we performed a retrospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf791db7d582d2a61271237d2115b6bc
https://doi.org/10.1111/bcpt.13799
https://doi.org/10.1111/bcpt.13799
Autor:
Yoshikazu TASAKI
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 53:193-195
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d44e87e9c17859c1df659a4bc4e9e5b6
https://doi.org/10.3999/jscpt.53.5_193
https://doi.org/10.3999/jscpt.53.5_193
Autor:
Takeshi, Chiba, Haruki, Ujiie, Yukiko, Yaegashi, Kengo, Umehara, Shinya, Takada, Koichi, Otaki, Ken-Ichi, Sako, Yuta, Nakamaru, Tomoji, Meada, Kenzo, Kudo, Yoshikazu, Tasaki, Hideki, Sato
Publikováno v:
Biomedical Reports. 17
This study aimed to investigate whether renin-angiotensin system inhibitors (RAS-I) have an advantage over calcium channel blockers (CCB) for suppression of proteinuria in hypertensive patients with gastric cancer receiving ramucirumab (RAM) treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfcd25dffcff4115e6d0f882c9d8ef45
https://doi.org/10.3892/br.2022.1559
https://doi.org/10.3892/br.2022.1559
Publikováno v:
In Vivo; May/Jun2023, Vol. 37 Issue 3, p1260-1265, 6p
Autor:
Ryosuke Takahashi, Sachiko Kasamo, Atsushi Yonezawa, Hitoshi Aizawa, Kazuo Matsubara, Masayoshi Kawata, Tomohiro Omura, Yosuke Taruno, Shota Yamamoto, Nobukatsu Sawamoto, Yoshikazu Tasaki, Hisako Endo, Joe Yamamoto
Publikováno v:
Journal of Neural Transmission. 128:27-36
In the pharmacotherapy of patients with Parkinson’s disease (PD), entacapone reduces the peripheral metabolism of l-dopa to 3-O-methyldopa (3-OMD), thereby prolonging the half-life (t1/2) of l-dopa and increasing the area under the concentration cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f286209471c405798813248ec3b8023b
https://doi.org/10.1007/s00702-020-02267-y
https://doi.org/10.1007/s00702-020-02267-y
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 46:567-575
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ecf356cbac4e1c93aacf5181ae68bd4
https://doi.org/10.5649/jjphcs.46.567
https://doi.org/10.5649/jjphcs.46.567
Autor:
Ryota Ishikawa, Seiji Matsumoto, Masahide Fukudo, Kazuto Mishima, Yoshikazu Tasaki, Takashi Ono
Publikováno v:
JCO Oncology Practice. 16:e1134-e1142
PURPOSE: Nivolumab dosage was initially selected on the basis of body weight, often resulting in leftover drug after sterile compounding. This study sought to investigate the real-world wastage of nivolumab and assess the long-term stability of lefto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abfda5a71cbe91dc7fee40f0e7a643ac
https://doi.org/10.1200/jop.19.00813
https://doi.org/10.1200/jop.19.00813